| 1/13/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Buy” from Brokerages |
rivertonroll.com |
NeoGenomics, Inc. (NASDAQ:NEO) Receives Average Rating of “Buy” from Brokerages Posted by William TylerShares of NeoGenomics , Inc. (NASDAQ:NEO) have been given an average rating of “Buy” by the fifteen analysts that are currently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has issued a strong buy recommendation on ... |
| 1/13/2021 |
Sanger Institute's COSMIC database licensed via Qiagen |
captodayonline.com |
Dec. 18, 2020—Beckman Coulter launched the Access SARS-CoV-2 Antigen assay, a high-throughput COVID-19 test... Webinars On Demand Tracking TRK with IHC: Today’s Diagnostic Algorithms for NTRK TestingWebinar presenter Lawrence M. Weiss, M D, Chief Medical Officer, NeoGenomics Laboratories, discusses the current diagnostic algorithms for NTRK testing, the role of IHC in testing for NTRK fusions in solid tumors, and implementing pan-TRK IHC ... |
| 1/12/2021 |
NeoGenomics (NASDAQ:NEO) PT Raised to $60.00 |
slatersentinel.com |
... from $50.00 to $60.00 in a research note published on Friday morning, AR Network reports. They currently have an outperform rating on the medical research company’s stock. SVB Leerink also issued estimates for NeoGenomics ’ Q4 2020 earnings at $0.03 EPS, Q3 2021 earnings at $0.06 EPS, FY2021 earnings at $0.24 EPS, Q1 2022 earnings at $0.09 EPS, Q2 2022 earnings at $0.10 EPS, Q3 2022 earnings at $0.12 ... |
| 1/11/2021 |
NeoGenomics (NASDAQ:NEO) Price Target Raised to $60.00 |
wkrb13.com |
... from $50.00 to $60.00 in a research note published on Friday morning, AnalystRatings.net reports. The firm currently has an outperform rating on the medical research company’s stock. SVB Leerink also issued estimates for NeoGenomics ’ Q4 2020 earnings at $0.03 EPS, Q3 2021 earnings at $0.06 EPS, FY2021 earnings at $0.24 EPS, Q1 2022 earnings at $0.09 EPS, Q2 2022 earnings at $0.10 EPS, Q3 2022 earnings at $0.12 ... |
| 1/11/2021 |
Needham Believes Thermo Fisher (TMO) Still Has Room to Grow |
markets.co |
... According to TipRanks.com , Unger is a 5-star analyst with an average return of 41.6% and a 78.2% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, PerkinElmer, and NeoGenomics .Currently, the analyst consensus on Thermo Fisher is a Strong Buy with an average price target of $534.08, representing a 4.9% upside. In a report issued on January 8, Credit Suisse also upgraded the stock ... |
| 1/11/2021 |
Needham Gives a Buy Rating to PerkinElmer (PKI) |
markets.co |
... to TipRanks.com , Unger is a 5-star analyst with an average return of 41.6% and a 78.2% success rate. Unger covers the Healthcare sector, focusing on stocks such as Myriad Genetics, Thermo Fisher, and NeoGenomics .The word on The Street in general, suggests a Moderate Buy analyst consensus rating for PerkinElmer with a $158.25 average price target, which is a -0.4% downside from current levels. In a report issued on ... |
| 1/11/2021 |
NeoGenomics $230 Million Common Stock Offering and $345 Million Convertible Senior Notes Offering |
davispolk.com |
NeoGenomics $230 Million Common Stock Offering and $345 Million Convertible Senior Notes Offering 1/11/2021 Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by NeoGenomics , Inc. of $345 million aggregate principal amount of its 0.250% convertible senior notes due 2028, which included $45 million aggregate principal amount of notes issued pursuant to the exercise in full of the underwriters’ option to purchase additional ... |
| 1/10/2021 |
NeoGenomics (NEO): A Genomic Stock Worth Checking? |
insidermonkey.com |
NeoGenomics Inc. (NASDAQ:NEO), founded in 2002, runs a laboratory network across the U.S., with a prime focus on cancer genetics diagnostic testing. It serves a wide range of customers including hospitals, pathologists, clinicians, and researchers, among others. The company says in its mission...[[ This is a content summary only. Visit my website for full links, other content, and more ... |
| 1/10/2021 |
Brokerages Set NeoGenomics, Inc. (NASDAQ:NEO) Price Target at $40.95 |
Ticker Report |
Shares of NeoGenomics, Inc. (NASDAQ:NEO) have been assigned a consensus rating of “Buy” from the fifteen ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on ... |
| 1/10/2021 |
SVB Leerink Increases NeoGenomics NEO) Price Target to $60.00 |
Ticker Report |
... Äúoutperform‚Äù rating on the medical research company‚Äôs stock. SVB Leerink‚Äôs target price would suggest a potential upside of 14.42% from the stock‚Äôs current price. SVB Leerink also issued estimates for NeoGenomics‚Äô Q4 2020 earnings at $0.03 EPS, Q3 2021 earnings at $0.06 EPS, FY2021 earnings at $0.24 EPS, Q1 2022 earnings at $0.09 EPS, Q2 2022 earnings at $0.10 EPS, Q3 2022 earnings at $0.12 ... |
| 1/9/2021 |
NeoGenomics (NASDAQ:NEO) Price Target Increased to $60.00 by Analysts at SVB Leerink |
zolmax.com |
... 60.00 in a research report sent to investors on Friday morning, AR Network reports. The firm currently has an outperform rating on the medical research company’s stock. SVB Leerink also issued estimates for NeoGenomics ’ Q4 2020 earnings at $0.03 EPS, Q3 2021 earnings at $0.06 EPS, FY2021 earnings at $0.24 EPS, Q1 2022 earnings at $0.09 EPS, Q2 2022 earnings at $0.10 EPS, Q3 2022 earnings at $0.12 ... |
| 1/9/2021 |
NeoGenomics (NASDAQ:NEO) PT Raised to $60.00 |
Daily Political |
NeoGenomics (NASDAQ:NEO) PT Raised to $60.00 January 9th, 2021 - Comments Off on NeoGenomics (NASDAQ:NEO) PT Raised to $60.00 - Filed Under - by Trevor Kearing TweetNeoGenomics (NASDAQ:NEO) had its price objective upped by SVB Leerink from $50.00 to $60.00 in a report published on Friday morning, AR Network reports. They currently have an outperform rating on the medical research company’s stock. SVB Leerink also issued estimates for ... |
| 1/8/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Receives $40.95 Average PT from Analysts |
Daily Political |
Shares of NeoGenomics , Inc. (NASDAQ:NEO) have been assigned an average rating of “Buy” from the fifteen analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokerages that have issued ratings on the stock in ... |
| 1/8/2021 |
SVB Leerink Boosts NeoGenomics (NASDAQ:NEO) Price Target to $60.00 |
Mayfield Recorder |
SVB Leerink Boosts NeoGenomics (NASDAQ:NEO) Price Target to $60.00 Posted by Charles Blunt on Jan 8th, 2021NeoGenomics (NASDAQ:NEO) had its target price increased by stock analysts at SVB Leerink from $50.00 to $60.00 in a research report issued on Friday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. SVB Leerink’s price objective would suggest a ... |
| 1/8/2021 |
SVB Leerink Boosts NeoGenomics (NASDAQ:NEO) Price Target to $60.00 |
coinblock.asia |
Charles Blunt 2021-01-08 11:01SVB Leerink Boosts NeoGenomics (NASDAQ:NEO) Price Target to $60.00 Posted by Charles Blunt on Jan 8th, 2021 NeoGenomics (NASDAQ:NEO) had its target price increased by stock analysts at SVB Leerink from $50.00 to $60.00 in a research report issued on Friday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. SVB Leerink’s price ... |
| 1/7/2021 |
The Ridgway Record |
ridgwayrecord.com |
FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics , Inc. ( NASDAQ:NEO ) (the " Company " ), a leading provider of cancer-focused genetics testing services and global oncology contract research services, today announced the pricing of concurrent underwritten public offerings of (a) 4,081,632 shares of its common stock at a public offering price of $49.00 per share (the "common stock offering") for gross proceeds to NeoGenomics from the common stock offering of $200.0 ... |
| 1/7/2021 |
NeoGenomics (NASDAQ:NEO) Trading Down 6.4% |
zolmax.com |
... increase of 115% from the average daily volume of 1,660,975 shares. The stock had previously closed at $54.84.NEO has been the topic of a number of recent research reports. ValuEngine lowered shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, November 2nd. Morgan Stanley initiated coverage on shares of NeoGenomics in a research note on Wednesday, September 9th. They ... |
| 1/7/2021 |
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes |
neogenomics.com |
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes Investor Relations Download as PDF January 06, 2021FORT MYERS, FL / ACCESSWIRE / January 6, 2021 / NeoGenomics , Inc. (NASDAQ:NEO) (the " Company " ), a leading provider of cancer-focused genetics the pricing of concurrent underwritten public offerings of (a) 4,081,632 shares of its common stock at a public offering price of $49.00 per share (the "common stock offering") for ... |
| 1/7/2021 |
NeoGenomics Prices $500M Offering of Stock, Senior Notes |
genomeweb.com |
staff reporterNEW YORK – NeoGenomics said late on Wednesday that it has priced a public offering of its common stock and convertible senior notes for a total of $500 million in gross proceeds.The Fort Myers, Florida-based firm is offering 4,081,632 shares of its common stock at $49.00 per share. It also is offering $300 million aggregate principal amount of its .25 percent convertible senior notes due January ... |
| 1/6/2021 |
NeoGenomics, Inc. (NASDAQ:NEO) Expected to Post Quarterly Sales of $124.66 Million |
rivertonroll.com |
NeoGenomics, Inc. (NASDAQ:NEO) Expected to Post Quarterly Sales of $124.66 Million Posted by Amelie Mason on Jan 6th, 2021 TweetWall Street brokerages expect NeoGenomics , Inc. (NASDAQ:NEO) to post sales of $124.66 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for NeoGenomics ’ earnings. The lowest sales estimate is $123.25 million and the highest is $125.40 million. NeoGenomics posted sales of $106.87 million ... |